Week in Review: Agilent Pays $250 Million to Acquire ACEA and its Cell Therapy Analyzer

Deals and Financings ACEA Biosciences, a San Diego-Hangzhou company that makes the xCELLigence® cell therapy analysis device, will be acquired by Agilent for $250 million; Zhejiang Anglikang Pharma of Shengzhou has been approved to stage an $87 million IPO on the Shenzhen SME Exchange; CSPC Pharmaceutical in-licensed China rights to an approved cancer treatment, Copitra™, from Verastem of Boston in a $45 million agreement; Cellular Biomedicine will provide China manufacturing for a Novartis CAR-T cell therapy, Kymriah®; Novartis will buy $40 million of CBMG stock; Shanghai Fosun Pharma in-licensed greater China rights to a candidate for stroke treatment from DiaMedica Therapeutics of Minneapolis in a $32.5 million agreement; Bellen Chemistry, a Beijing process CRO/CMO, raised "hundreds of millions in RMB" ($30 million plus) in a C round; WuXi Biologics formed a collaboration with I-Mab Biopharma to develop three bi-specific antibodies, using WuXi 's proprietary WuXiBody™ Platform; Flow Pharma, a San Francisco Bay Area biotech, formed a China JV with Button Capital, a US investor, to conduct China clinical trials of its therapeutic cancer vaccines; Everest Medicines II, a US-China in-licensing company, acquired China and Southeast Asia rights to a VenatoRx treatment for drug-resistant infections. Stock Symbols: (NYSE: A) (HK: 1093) (NSDQ: VSTM) (NSDQ: CBMG) (NYSE: NVS) (HK: 02196: SHA: 600196) (TSX: DMA; OTCQB: DMCAF) (HK: 2269) Share this with colleagues: // //